(Q46294946)

21 December 2017

title

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia (English)

1 reference

21 December 2017

1 reference

1

1 reference

21 December 2017

Fabrizio Gardoni

3

1 reference

21 December 2017

Thomas Carlsson

6

1 reference

21 December 2017

Monica Di Luca

8

1 reference

21 December 2017

Anders Björklund

9

1 reference

21 December 2017

Erwan Bezard

10

1 reference

21 December 2017

Manolo Carta

object named as

Manolo Carta

11

0 references

author name string

Qin Li

2

1 reference

21 December 2017

Elena Marcello

4

1 reference

21 December 2017

Chuan Qin

5

1 reference

21 December 2017

Deniz Kirik

7

1 reference

21 December 2017

language of work or name

English

0 references

publication date

24 October 2008

1 reference

21 December 2017

published in

Brain

1 reference

21 December 2017

volume

131

1 reference

21 December 2017

issue

Pt 12

1 reference

21 December 2017

page(s)

3380-3394

1 reference

21 December 2017

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Effects of sarizotan on the corticostriatal glutamate pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

DAncing past the DAT at a DA synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

L-Dopa-Induced Release of Cerebral Monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Levodopa motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWN235

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWN235

1 reference

21 December 2017

1 reference

21 December 2017